文献速递冠心病

收缩压与微轴流泵治疗心梗相关心源性休克生存获益的关联

Systolic Blood Pressure and Microaxial Flow Pump-Associated Survival in Infarct-Related Cardiogenic Shock: A Post Hoc Analysis of the DanGer Shock Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2025-01-01

该研究为DanGer Shock随机临床试验的事后分析,纳入351例ST段抬高型心肌梗死合并心源性休克患者,按随机化时收缩压(SBP)评估微轴流泵治疗对180天全因死亡率的影响。结论提示早期SBP可能有助于识别最可能获益的患者,但为假说生成性发现。

要点

  • SBP<82 mmHg的STEMI合并心源性休克患者接受微轴流泵治疗生存获益显著。
  • SBP≥82 mmHg者未观察到微轴流泵治疗的显著生存获益。
  • 早期SBP可能作为筛选微轴流泵治疗获益人群的参考指标。

核心结论

  • 随机化时收缩压与微轴流泵治疗的生存获益相关,血压最低的患者获益最大。
  • 早期收缩压可能有助于识别最可能从微轴流泵治疗中获得净获益的患者。
  • 研究结果为假说生成性。

研究设计与样本

  • DanGer Shock开放标签随机临床试验的事后分析。
  • 纳入355例ST段抬高型心肌梗死合并心源性休克成人患者,其中351例有随机化时收缩压数据。
  • 2013至2023年在丹麦、德国和英国的14个三级侵入性心脏中心开展。
  • 干预为微轴流泵治疗联合标准治疗 vs 单纯标准治疗。
  • 主要终点为随机化收缩压分组的180天全因死亡率。

主要发现

  • 351例患者中位年龄69岁(IQR 59-76),277例(79%)为男性。

临床怎么用

  • 对于STEMI合并心源性休克且收缩压较低(<82 mmHg)的患者,可考虑微轴流泵治疗以改善生存。
  • 收缩压较高的患者使用微轴流泵的获益不明确,需个体化评估。
  • 早期收缩压可作为临床决策的参考因素之一。

局限性

  • 为事后分析,结果属假说生成性。
  • 样本量有限(351例有收缩压数据)。
  • 仅纳入ST段抬高型心肌梗死相关心源性休克患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Microaxial flow pump treatment improves survival in selected patients with infarct-related cardiogenic shock; however, treatment carries substantial risks, and benefit may vary by patient subgroup. Systolic blood pressure (SBP) has been proposed as a modifier of the survival benefit. OBJECTIVE: To investigate whether SBP at randomization modifies the survival benefit of microaxial flow pump treatment in ST-segment elevation myocardial infarction-related cardiogenic shock. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the Danish-German (DanGer) Shock open-label randomized clinical trial among adult patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock, conducted between 2013 and 2023 at 14 tertiary invasive cardiac centers in Denmark, Germany, and the United Kingdom. Data analysis was performed from January 7 to April 7, 2024. INTERVENTION: Microaxial flow pump therapy plus standard care vs standard care alone. MAIN OUTCOMES AND MEASURES: All-cause mortality at 180 days according to randomization SBP. RESULTS: Of 355 patients included in the DanGer Shock trial, 351 patients had available SBP at randomization (median [IQR] age, 69 [59-76] years; 277 [79%] male). In a dichotomized regression analysis, microaxial flow pump treatment significantly reduced mortality for SBPs lower than 82 mm Hg compared with standard care alone (odds ratio [OR], 0.34; 95% CI, 0.18-0.63; P < .001). This was not evident for higher pressures (OR, 0.96; 95% CI, 0.53-1.70; P = .90; P for interaction = .02). Kaplan-Meier survival analysis and spline regression analysis supported these findings (P for interaction = .02; P for nonlinearity = .01). CONCLUSIONS AND RELEVANCE: Randomization SBP was associated with the survival benefit of microaxial flow pump treatment, with the most hypotensive patients deriving the largest survival benefit. Early SBP may help identify patients most likely to gain a net benefit from microaxial flow pump treatment. Findings are hypothesis generating. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01633502.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Mikkelsen, Beske, Jensen, et al. Systolic Blood Pressure and Microaxial Flow Pump-Associated Survival in Infarct-Related Cardiogenic Shock: A Post Hoc Analysis of the DanGer Shock Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 40884241. doi:10.1001/jamacardio.2025.3337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。